Vulvar Cancer Therapeutics Market Share Analysis, Trends and Growth Forecast 2026-2031

Vulvar Cancer Therapeutics Market Share Analysis, Trends and Growth Forecast 2026-2031 Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Vulvar Cancer Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global vulvar cancer therapeutics market was valued at USD 0.67 billion in 2025 and is projected to increase from USD 0.74 billion in 2026 to USD 1.21 billion by 2031. The market is expected to register a compound annual growth rate of 10.30% during the 2026-2031 forecast period. Growth is supported by the rising incidence of HPV-associated vulvar cancer, expanding immunotherapy use, biomarker-driven treatment selection, and increased clinical trial activity in rare gynecologic oncology.

HPV-Associated Cases Expand the Addressable Treatment Population

Increasing HPV-positive vulvar cancer incidence is enlarging the treatment pool, particularly among older women. HPV-positive cases in the 55-64 age group increased by 53% between 2000 and 2024, indicating sustained demand for systemic and multimodal treatment. Germany, the Netherlands, and Canada report comparatively high age-standardized incidence rates, creating opportunities in countries with established oncology infrastructure and healthcare spending.

Although HPV vaccination is expected to reduce the long-term disease burden, its effect on the treated population is unlikely to become significant during the current forecast period. Patients diagnosed in the near term will continue to support demand for surgery, radiation therapy, chemotherapy, biologic therapy, targeted therapy, and immunotherapy.

Immunotherapy and Biomarker-Driven Care Support Market Growth

Immunotherapy is moving from a limited salvage option toward more structured vulvar cancer treatment pathways. Phase 2 findings reported in 2025 showed that pembrolizumab combined with cisplatin-sensitized radiation, followed by pembrolizumab maintenance, achieved a 75% objective response rate, a 37.5% complete response rate, and a 70% six-month recurrence-free survival rate in unresectable vulvar squamous cell carcinoma.

Additional evidence from a 2025 systematic review and meta-analysis supported the use of immune checkpoint inhibitors in advanced vulvar cancer, citing encouraging response patterns and manageable toxicity. Treatment decisions are also becoming increasingly linked to biomarkers such as PD-L1, MSI-H, and TMB-H status, strengthening the role of precision oncology in eligible patient populations.

Limited Patient Numbers Remain a Commercial Constraint

The relatively small patient population continues to affect clinical trial recruitment, pricing strategies, reimbursement decisions, and dedicated commercial investment. GLOBOCAN estimates 47,336 new vulvar cancer cases worldwide, while the United States is projected to record 7,130 cases in 2026.

Limited enrollment potential makes large Phase 3 trials difficult to conduct, leaving many development programs dependent on single-arm studies or smaller randomized Phase 2 trials. This can delay payer decisions when mature survival evidence is required. Pharmaceutical companies may also favor tumor-agnostic approval pathways rather than investing in disease-specific commercialization platforms.

Other factors shaping the vulvar cancer therapeutics market include:

Vulvar Cancer Therapeutics Market Segment Analysis

Biologic therapy is expected to account for 28.58% of the vulvar cancer therapeutics market in 2025, reflecting its established role in treatment. Immunotherapy is forecast to record a CAGR of 11.45% between 2026 and 2031, outpacing the broader market as biomarker-based patient selection and combination treatment strategies become more widely adopted.

The report segments the market by treatment type, cancer type, end user, and geography. Treatment categories include surgery, chemotherapy, radiation therapy, biologic therapy, targeted therapy, and immunotherapy. Cancer types covered include vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, basal cell carcinoma, and other vulvar malignancies. End users include hospitals, specialty clinics, cancer research institutes, and other healthcare settings.

Regional Market Outlook

North America is expected to remain the largest regional market, supported by advanced oncology infrastructure, higher treatment availability, and wider adoption of biomarker-linked therapies. The United States is the principal contributor, aided by the FDA's tumor-agnostic framework for pembrolizumab access in selected cancers. Age-adjusted vulvar cancer incidence in the country increased by 0.6% annually from 2014 to 2024, while mortality rose by 1.9% annually from 2015 to 2024. Canada also presents a notable opportunity, while Mexico's growth is concentrated in major urban treatment centers.

Europe is projected to remain the second-largest regional contributor, led by Germany, France, and the United Kingdom. France's UNICANCER AcSe Immunotherapy program expanded study access for rare dMMR/MSI-H cancers, including vulvar cancer, across 24 centers beginning in July 2024. However, differences in reimbursement requirements and time to therapy availability continue to create uneven access across European markets.

Asia-Pacific is forecast to be the fastest-growing region, registering a CAGR of 11.56% from 2026 to 2031. Expansion is being driven by rising oncology capacity, large patient populations, private hospital investment, and stronger regulatory attention to rare cancers. Japan, South Korea, and Australia benefit from advanced treatment systems and clinical research participation, while China and India represent significant volume opportunities. Brazil and Argentina lead South America, while GCC countries and South Africa are the principal markets in the Middle East and Africa.

Key Topics Covered

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Incidence of HPV-Associated Vulvar Squamous Cell Carcinoma

4.2.2 Expanding Immunotherapy and Biomarker-Driven Treatment Use

4.2.3 Increasing Clinical Trial Activity in Rare Gynecologic Oncology

4.2.4 Wider Adoption of Multimodal Treatment Pathways in Advanced Disease

4.2.5 Improved Sentinel Node and Imaging-Guided Surgical Planning

4.2.6 Earlier Molecular Profiling for HPV-Independent Tumors

4.3 Market Restraints

4.3.1 Small Patient Pool Limiting Commercial Scale

4.3.2 High Treatment Cost and Reimbursement Friction for Novel Agents

4.3.3 Limited Labelled Indications and Sparse Pivotal Data

4.3.4 Post-Surgical Morbidity and Quality-of-Life Concerns Affecting Adoption

4.4 Supply/Value Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces Analysis

4.7.1 Bargaining Power of Suppliers

4.7.2 Bargaining Power of Buyers

4.7.3 Threat of New Entrants

4.7.4 Threat of Substitutes

4.7.5 Intensity of Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

5.1 By Treatment Type

5.1.1 Surgery

5.1.2 Chemotherapy

5.1.3 Radiation Therapy

5.1.4 Biologic Therapy

5.1.5 Targeted Therapy

5.1.6 Immunotherapy

5.2 By Cancer Type

5.2.1 Vulvar Squamous Cell Carcinoma

5.2.2 Vulvar Melanoma

5.2.3 Adenocarcinoma

5.2.4 Basal Cell Carcinoma

5.2.5 Other Vulvar Malignancies

5.3 By End User

5.3.1 Hospitals

5.3.2 Specialty Clinics

5.3.3 Cancer Research Institutes

5.3.4 Others

5.4 By Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 India

5.4.3.3 Japan

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)

6.3.1 AbbVie Inc.

6.3.2 Amgen Inc.

6.3.3 AstraZeneca PLC

6.3.4 Bayer AG

6.3.5 Bristol-Myers Squibb Company

6.3.6 Eli Lilly and Company

6.3.7 F. Hoffmann-La Roche Ltd

6.3.8 GSK plc

6.3.9 ISA Pharmaceuticals B.V.

6.3.10 Johnson and Johnson

6.3.11 Merck & Co., Inc.

6.3.12 Novartis AG

6.3.13 Ono Pharmaceutical Co., Ltd.

6.3.14 PDS Biotechnology Corporation

6.3.15 Pfizer Inc.

6.3.16 Sanofi SA

6.3.17 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

7.1 White Space and Unmet Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/kx511f

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.